Review of Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome

doi:10.12114/j.issn.1007-9572.2022.02.011

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (15): 1807-1813.DOI: 10.12114/j.issn.1007-9572.2022.02.011

• Hot Research: Irritable Bowel Syndrome • Previous Articles Next Articles

Review of Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome

1. School of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
2. Affiliated Hospital/Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
3. School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China

Received:2021-12-07 Revised:2022-01-10 Published:2022-01-27 Online:2022-04-07
Contact: Shuguang YU
About author:
SHI Y Z, ZHENG H, CHEN M, et al. Review of complementary and alternative medicine therapies for irritable bowel syndrome[J]. Chinese General Practice, 2022, 25 (15) : 1807-1813.

补充与替代疗法治疗肠易激综合征的研究进展

1. 610075　四川省成都市，成都中医药大学针灸推拿学院
2. 610075　四川省成都市，成都中医药大学附属医院/临床医学院;
3. 100029　北京市，北京中医药大学针灸推拿学院

通讯作者: 余曙光
作者简介:
石云舟，郑晖，陈敏，等.补充与替代疗法治疗肠易激综合征的研究进展[J].中国全科医学，2022，25（15）：1807-1813.[www.chinagp.net] 作者贡献：石云舟、郑晖提出文章写作思路；石云舟制定文献检索策略，进行文献/资料收集、整理、翻译，并撰写论文初稿；陈敏进行论文的修订；郑晖、李志刚、余曙光对论文进行审校；石云舟、余曙光对文章整体负责，监督管理；所有作者确认了论文终稿。
基金资助:
国家重点研发计划"中医药现代化研究"重点专项(2019YFC1709004)

Abstract

Abstract:

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder frequently encountered clinically. Many IBS patients use complementary and alternative medicine (CAM) therapies for better treatment results when their conditions could not be improved by first-line drug treatment. However, due to limitations of quality and quantity of studies about CAM therapies, most of these therapies for IBS have not been recommended by relevant consensuses and guidelines. We overviewed common CAM therapies for IBS, detailed three types, namely, natural products, psychosomatic therapies, and Chinese medicine, aiming at increasing clinical workers and patients' understanding and application of these therapies.

Key words: Irritable bowel syndrome, Complementary and alternative medicine, Treatments, Review

摘要：

肠易激综合征是临床常见的功能性胃肠病之一。由于多数患者的症状经过一线药物治疗后仍不能得到较好改善，许多患者为获得更好的治疗效果，转向选择补充与替代疗法进行治疗。然而，由于研究质量和数量的限制，大部分治疗肠易激综合征的补充与替代疗法并未被相关共识和指南所推荐。本文从补充与替代疗法的分类入手，从天然产品、身心治疗、传统医药3个方面就目前国内外常用的补充与替代疗法治疗肠易激综合征的研究进行概述，以期为临床工作者和患者更好地了解和应用提供帮助。

关键词: 肠易激综合征, 补充与替代疗法, 治疗方法, 综述

Yunzhou SHI,Hui ZHENG,Min CHEN, et al. Review of Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome[J]. Chinese General Practice, 2022, 25(15): 1807-1813. DOI: 10.12114/j.issn.1007-9572.2022.02.011.
石云舟,郑晖,陈敏等. 补充与替代疗法治疗肠易激综合征的研究进展[J]. 中国全科医学, 2022, 25(15): 1807-1813. DOI: 10.12114/j.issn.1007-9572.2022.02.011.

References 85

[1]	DROSSMAN D A, HASLER W L. RomeⅣ-functional GI disorders：disorders of gut-brain interaction[J]. Gastroenterology，2016，150（6）：1257-1261. DOI：10.1053/j.gastro.2016.03.035.
[2]	MAKKER J, CHILIMURI S, BELLA J N. Genetic epidemiology of irritable bowel syndrome[J]. World J Gastroenterol，2015，21（40）：11353-11361. DOI：10.3748/wjg.v21.i40.11353.
[3]	ZHOU Q Q, ZHANG B Y, VERNE G N. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome[J]. Pain，2009，146（1/2）：41-46. DOI：10.1016/j.pain.2009.06.017.
[4]	DROSSMAN D A, TACK J, FORD A C，et al. Neuromodulators for functional gastrointestinal disorders （disorders of gut-brain interaction）：a Rome foundation working team report[J]. Gastroenterology，2018，154（4）：1140-1171.e1. DOI：10.1053/j.gastro.2017.11.279.
[5]	FORD A C, TALLEY N J. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome：a systematic review[J]. J Gastroenterol，2011，46（4）：421-431. DOI：10.1007/s00535-011-0379-9.
[6]	O'MAHONY S M, CLARKE G, DINAN T G，et al. Irritable bowel syndrome and stress-related psychiatric co-morbidities：focus on early life stress[J]. Handb Exp Pharmacol，2017，239：219-246. DOI：10.1007/164_2016_128.
[7]	SINGH P, LEMBO A. Emerging role of the gut microbiome in irritable bowel syndrome[J]. Gastroenterol Clin North Am，2021，50（3）：523-545. DOI：10.1016/j.gtc.2021.03.003.
[8]	DEFREES D N, BAILEY J. Irritable bowel syndrome：epidemiology，pathophysiology，diagnosis，and treatment[J]. Prim Care，2017，44（4）：655-671. DOI：10.1016/j.pop.2017.07.009.
[9]	LOVELL R M, FORD A C. Global prevalence of and risk factors for irritable bowel syndrome：a meta-analysis[J]. Clin Gastroenterol Hepatol，2012，10（7）：712-721.e4. DOI：10.1016/j.cgh.2012.02.029.
[10]	XIONG L S, CHEN M H, CHEN H X，et al. A population-based epidemiologic study of irritable bowel syndrome in South China：stratified randomized study by cluster sampling[J]. Aliment Pharmacol Ther，2004，19（11）：1217-1224. DOI：10.1111/j.1365-2036.2004.01939.x.
[11]	LIU J S, HOU X H. A review of the irritable bowel syndrome investigation on epidemiology，pathogenesis and pathophysiology in China[J]. J Gastroenterol Hepatol，2011，26（Suppl 3）：88-93. DOI：10.1111/j.1440-1746.2011.06641.x.
[12]	BLACK C J, FORD A C. Global burden of irritable bowel syndrome：trends，predictions and risk factors[J]. Nat Rev Gastroenterol Hepatol，2020，17（8）：473-486. DOI：10.1038/s41575-020-0286-8.
[13]	EVERHART J E, RUHL C E. Burden of digestive diseases in the United States partⅡ：lower gastrointestinal diseases[J]. Gastroenterology，2009，136（3）：741-754. DOI：10.1053/j.gastro.2009.01.015.
[14]	SIMRÉN M, TÖRNBLOM H, PALSSON O S，et al. Management of the multiple symptoms of irritable bowel syndrome[J]. Lancet Gastroenterol Hepatol，2017，2（2）：112-122. DOI：10.1016/S2468-1253(16)30116-9.
[15]	MOAYYEDI P, ANDREWS C N, MACQUEEN G，et al. Canadian association of gastroenterology clinical practice guideline for the management of irritable bowel syndrome （IBS）[J]. J Can Assoc Gastroenterol，2019，2（1）：6-29. DOI：10.1093/jcag/gwy071.
[16]	BIJKERK C J, DE WIT N J, MURIS J W M，et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial[J]. BMJ，2009，339：b3154. DOI：10.1136/bmj.b3154.
[17]	ZHENG L, LAI Y L, LU W M，et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter，randomized，controlled trial[J]. Clin Gastroenterol Hepatol，2015，13（7）：1285-1292.e1. DOI：10.1016/j.cgh.2015.01.015.
[18]	SAITO Y A, ALMAZAR A E, TILKES K E，et al. Randomised clinical trial：pregabalin vs placebo for irritable bowel syndrome[J]. Aliment Pharmacol Ther，2019，49（4）：389-397. DOI：10.1111/apt.15077.
[19]	EL-AYACHE N, GALLIGAN J J. 5-HT3 receptor signaling in serotonin transporter-knockout rats：a female sex-specific animal model of visceral hypersensitivity[J]. Am J Physiol Gastrointest Liver Physiol，2019，316（1）：G132-143. DOI：10.1152/ajpgi.00131.2018.
[20]	JONES J, LEMBO A, HEIDELBAUGH J，et al. Management of irritable bowel syndrome with diarrhea：focus on eluxadoline[J]. Curr Med Res Opin，2021，37（4）：567-578. DOI：10.1080/03007995.2021.1888705.
[21]	BRENNER D M, FOGEL R, DORN S D，et al. Efficacy，safety，and tolerability of plecanatide in patients with irritable bowel syndrome with constipation：results of two phase 3 randomized clinical trials[J]. Am J Gastroenterol，2018，113（5）：735-745. DOI：10.1038/s41395-018-0026-7.
[22]	HÄUSER W, MARSCHALL U, LAYER P，et al. The prevalence，comorbidity，management and costs of irritable bowel syndrome[J]. Dtsch Arztebl Int，2019，116（27/28）：463-470. DOI：10.3238/arztebl.2019.0463.
[23]	KOLOSKI N A, TALLEY N J, HUSKIC S S，et al. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia[J]. Aliment Pharmacol Ther，2003，17（6）：841-851. DOI：10.1046/j.1365-2036.2003.01498.x.
[24]	KONG S C, HURLSTONE D P, POCOCK C Y，et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases[J]. J Clin Gastroenterol，2005，39（2）：138-141.
[25]	张杨蓉，陈一斌. 中医药治疗便秘型肠易激综合征研究进展[J]. 中国医药导刊，2021，23（8）：565-568. DOI：10.3969/j.issn.1009-0959.2021.08.002.
[26]	LARUSSA T, ROSSI M, SURACI E，et al. Use of complementary and alternative medicine by patients with irritable bowel syndrome according to the RomaⅣ criteria：a single-center Italian survey[J]. Medicina （Kaunas），2019，55（2）：46. DOI：10.3390/medicina55020046.
[27]	LIU J P, YANG M, LIU Y X，et al. Herbal medicines for treatment of irritable bowel syndrome[J]. Cochrane Database Syst Rev，2006（1）：CD004116. DOI：10.1002/14651858.CD004116.pub2.
[28]	WERAWATGANON D, RAKANANURAK N, SALLAPANT S，et al. Aloe vera attenuated gastric injury on indomethacin-induced gastropathy in rats[J]. World J Gastroenterol，2014，20（48）：18330-18337. DOI：10.3748/wjg.v20.i48.18330.
[29]	HONG S W, CHUN J, PARK S，et al. Aloe vera is effective and safe in short-term treatment of irritable bowel syndrome：a systematic review and meta-analysis[J]. J Neurogastroenterol Motil，2018，24（4）：528-535. DOI：10.5056/jnm18077.
[30]	YANG H N, KIM D J, KIM Y M，et al. Aloe-induced toxic hepatitis[J]. J Korean Med Sci，2010，25（3）：492-495. DOI：10.3346/jkms.2010.25.3.492.
[31]	高榆嘉，张文静，刘萌，等. 薄荷药理作用的研究进展[J]. 吉林医药学院学报，2020，41（3）：215-217. DOI：10.13845/j.cnki.issn1673-2995.2020.03.024.
[32]	CHUMPITAZI B P, KEARNS G L, SHULMAN R J. Review article：the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders[J]. Aliment Pharmacol Ther，2018，47（6）：738-752. DOI：10.1111/apt.14519.
[33]	ALAMMAR N, WANG L, SABERI B，et al. The impact of peppermint oil on the irritable bowel syndrome：a meta-analysis of the pooled clinical data[J]. BMC Complement Altern Med，2019，19（1）：21. DOI：10.1186/s12906-018-2409-0.
[34]	FORD A C, MOAYYEDI P, CHEY W D，et al. American college of gastroenterology monograph on management of irritable bowel syndrome[J]. Am J Gastroenterol，2018，113（Suppl 2）：1-18. DOI：10.1038/s41395-018-0084-x.
[35]	WILKINSON S M, BECK M H. Allergic contact dermatitis from menthol in peppermint[J]. Contact Dermatitis，1994，30（1）：42-43. DOI：10.1111/j.1600-0536.1994.tb00728.x.
[36]	BOURGEOIS P, GOOSSENS A. Allergic contact cheilitis caused by menthol in toothpaste and throat medication：a case report[J]. Contact Dermatitis，2016，75（2）：113-115. DOI：10.1111/cod.12571.
[37]	ALLESCHER H D, ABDEL-AZIZ H. Mechanism of action of STW 5 in functional dyspepsia and IBS：the origin of multi-target[J]. Dig Dis，2017，35（Suppl 1）：18-24. DOI：10.1159/000485456.
[38]	MADISCH A, HOLTMANN G, PLEIN K，et al. Treatment of irritable bowel syndrome with herbal preparations：results of a double-blind，randomized，placebo-controlled，multi-centre trial[J]. Aliment Pharmacol Ther，2004，19（3）：271-279. DOI：10.1111/j.1365-2036.2004.01859.x.
[39]	张伟，孙建华，裴丽霞，等. 中医药治疗肠易激综合征的系统评价/Meta分析的再评价[J]. 世界华人消化杂志，2014，22（12）：1747-1755.
[40]	ACHAMRAH N, DÉCHELOTTE P, COËFFIER M. Glutamine and the regulation of intestinal permeability：from bench to bedside[J]. Curr Opin Clin Nutr Metab Care，2017，20（1）：86-91. DOI：10.1097/MCO.0000000000000339.
[41]	陈晓敏，罗云，江敏，等. 结肠黏膜褪黑素受体表达与肠易激综合征症状相关性研究[J]. 胃肠病学和肝病学杂志，2015，24（8）：943-945. DOI：10.3969/j.issn.1006-5709.2015.08.013.
[42]	陈晓敏，江敏，罗云，等. 褪黑素治疗伴有睡眠障碍的肠易激综合征的临床研究[J]. 深圳中西医结合杂志，2015，25（2）：1-3. DOI：10.16458/j.cnki.1007-0893.2015.02.001.
[43]	SIAH K T, WONG R K, HO K Y. Melatonin for the treatment of irritable bowel syndrome[J]. World J Gastroenterol，2014，20（10）：2492-2498. DOI：10.3748/wjg.v20.i10.2492.
[44]	BARBALHO S M, GOULART R A, ARAÚJO A C，et al. Irritable bowel syndrome：a review of the general aspects and the potential role of vitamin D[J]. Expert Rev Gastroenterol Hepatol，2019，13（4）：345-359. DOI：10.1080/17474124.2019.1570137.
[45]	ABBASNEZHAD A, AMANI R, HASANVAND A，et al. Association of serum vitamin D concentration with clinical symptoms and quality of life in patients with irritable bowel syndrome[J]. J Am Coll Nutr，2019，38（4）：327-333. DOI：10.1080/07315724.2018.1510349.
[46]	GLABSKA D, KOLOTA A, LACHOWICZ K，et al. Vitamin D supplementation and mental health in inflammatory bowel diseases and irritable bowel syndrome patients：a systematic review[J]. Nutrients，2021，13（10）：3662. DOI：10.3390/nu13103662.
[47]	JALILI M, VAHEDI H, POUSTCHI H，et al. Effects of vitamin D supplementation in patients with irritable bowel syndrome：a randomized，double-blind，placebo-controlled clinical trial[J]. Int J Prev Med，2019，10：16. DOI：10.4103/ijpvm.IJPVM_512_17.
[48]	KHALIGHI SIKAROUDI M, MOKHTARE M, JANANI L，et al. Vitamin D3 supplementation in diarrhea-predominant irritable bowel syndrome patients：the effects on symptoms improvement，serum corticotropin-releasing hormone，and interleukin-6 - a randomized clinical trial[J]. Complement Med Res，2020，27（5）：302-309. DOI：10.1159/000506149.
[49]	PLUDOWSKI P, HOLICK M F, GRANT W B，et al. Vitamin D supplementation guidelines[J]. J Steroid Biochem Mol Biol，2018，175：125-135. DOI：10.1016/j.jsbmb.2017.01.021.
[50]	DROSSMAN D A, HASLER W L. RomeⅣ-functional GI disorders：disorders of gut-brain interaction[J]. Gastroenterology，2016，150（6）：1257-1261. DOI：10.1053/j.gastro.2016.03.035.
[51]	GWEE K A, GONLACHANVIT S, GHOSHAL U C，et al. Second Asian consensus on irritable bowel syndrome[J]. J Neurogastroenterol Motil，2019，25（3）：343-362. DOI：10.5056/jnm19041.
[52]	KOLOSKI N A, JONES M, KALANTAR J，et al. The brain—gut pathway in functional gastrointestinal disorders is bidirectional：a 12-year prospective population-based study[J]. Gut，2012，61（9）：1284-1290. DOI：10.1136/gutjnl-2011-300474.
[53]	中华医学会消化病学分会胃肠功能性疾病协作组，中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J]. 中华消化杂志，2020，40（12）：803-818. DOI：10.3760/cma.j.cn311367-20201116-00660.
[54]	李彦楠，杨丽旋，赵钟辉，等. 《2020年中国肠易激综合征专家共识意见》解读[J]. 中国临床医生杂志，2021，49（10）：1151-1155. DOI：10.3969/j.issn.2095-8552.2021.10.006.
[55]	KOLOSKI N, HOLTMANN G, TALLEY N J. Is there a causal link between psychological disorders and functional gastrointestinal disorders? [J]. Expert Rev Gastroenterol Hepatol，2020，14（11）：1047-1059. DOI：10.1080/17474124.2020.1801414.
[56]	LACKNER J M. Skills over pills? A clinical gastroenterologist's primer in cognitive behavioral therapy for irritable bowel syndrome[J]. Expert Rev Gastroenterol Hepatol，2020，14（7）：601-618. DOI：10.1080/17474124.2020.1780118.
[57]	ZIJDENBOS I L, DE WIT N J, VAN DER HEIJDEN G J，et al. Psychological treatments for the management of irritable bowel syndrome[J]. Cochrane Database Syst Rev，2009（1）：CD006442. DOI：10.1002/14651858.CD006442.pub2.
[58]	EVERITT H A, LANDAU S, O'REILLY G，et al. Assessing telephone-delivered cognitive-behavioural therapy （CBT） and web-delivered CBT versus treatment as usual in irritable bowel syndrome （ACTIB）：a multicentre randomised trial[J]. Gut，2019，68（9）：1613-1623. DOI：10.1136/gutjnl-2018-317805.
[59]	EVERITT H, LANDAU S, LITTLE P，et al. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome：the ACTIB three-arm RCT[J]. Health Technol Assess，2019，23（17）：1-154. DOI：10.3310/hta23170.
[60]	EVERITT H A, LANDAU S, O'REILLY G，et al. Cognitive behavioural therapy for irritable bowel syndrome：24-month follow-up of participants in the ACTIB randomised trial[J]. Lancet Gastroenterol Hepatol，2019，4（11）：863-872. DOI：10.1016/S2468-1253(19)30243-2.
[61]	WEBB A N, KUKURUZOVIC R H, CATTO-SMITH A G，et al. Hypnotherapy for treatment of irritable bowel syndrome[J]. Cochrane Database Syst Rev，2007（4）：CD005110. DOI：10.1002/14651858.CD005110.pub2.
[62]	MOSER G, TRÄGNER S, GAJOWNICZEK E E，et al. Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome：a randomized controlled trial[J]. Am J Gastroenterol，2013，108（4）：602-609. DOI：10.1038/ajg.2013.19.
[63]	FLIK C E, LAAN W, ZUITHOFF N P A，et al. Efficacy of individual and group hypnotherapy in irritable bowel syndrome （IMAGINE）：a multicentre randomised controlled trial[J]. Lancet Gastroenterol Hepatol，2019，4（1）：20-31. DOI：10.1016/S2468-1253(18)30310-8.
[64]	D'SILVA A, MACQUEEN G, NASSER Y，et al. Yoga as a therapy for irritable bowel syndrome[J]. Dig Dis Sci，2020，65（9）：2503-2514. DOI：10.1007/s10620-019-05989-6.
[65]	SCHUMANN D, ANHEYER D, LAUCHE R，et al. Effect of Yoga in the therapy of irritable bowel syndrome：a systematic review[J]. Clin Gastroenterol Hepatol，2016，14（12）：1720-1731. DOI：10.1016/j.cgh.2016.04.026.
[66]	TAVAKOLI T, DAVOODI N, JAFAR TABATABAEE T S，et al. Comparison of laughter Yoga and anti-anxiety medication on anxiety and gastrointestinal symptoms of patients with irritable bowel syndrome[J]. Middle East J Dig Dis，2019，11（4）：211-217. DOI：10.15171/mejdd.2019.151.
[67]	HENRICH J F, GJELSVIK B, SURAWY C，et al. A randomized clinical trial of mindfulness-based cognitive therapy for women with irritable bowel syndrome-effects and mechanisms[J]. J Consult Clin Psychol，2020，88（4）：295-310. DOI：10.1037/ccp0000483.
[68]	GAYLORD S A, PALSSON O S, GARLAND E L，et al. Mindfulness training reduces the severity of irritable bowel syndrome in women：results of a randomized controlled trial[J]. Am J Gastroenterol，2011，106（9）：1678-1688. DOI：10.1038/ajg.2011.184.
[69]	NALIBOFF B D, SMITH S R, SERPA J G，et al. Mindfulness-based stress reduction improves irritable bowel syndrome （IBS） symptoms via specific aspects of mindfulness[J]. Neurogastroenterol Motil，2020，32（9）：e13828. DOI：10.1111/nmo.13828.
[70]	王文，张莎，朱芳红. 肠易激综合征的中医药治疗现状与分析[J]. 中国中医急症，2020，29（4）：750-752. DOI：10.3969/j.issn.1004-745X.2020.04.054.
[71]	中华中医药学会脾胃病分会. 肠易激综合征中医诊疗专家共识意见（2017）[J]. 中医杂志，2017，58（18）：1614-1620. DOI：10.13288/j.11-2166/r.2017.18.024.
[72]	ZHU J J, LIU S, SU X L，et al. Efficacy of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome：a meta-analysis of randomized，double-blind，placebo-controlled trials[J]. Evid Based Complement Alternat Med，2016，2016：4071260. DOI：10.1155/2016/4071260.
[73]	WU Y B, DAI Y K, ZHANG L，et al. Pharmacological treatments of Chinese herbal medicine for irritable bowel syndrome in adults：a network meta-analysis of randomized controlled trials[J]. PLoS One，2021，16（8）：e0255665. DOI：10.1371/journal.pone.0255665.
[74]	XIAO Y, LIU Y Y, HUANG S H，et al. The efficacy of Shugan Jianpi Zhixie therapy for diarrhea-predominant irritable bowel syndrome：a meta-analysis of randomized，double-blind，placebo-controlled trials[J]. PLoS One，2015，10（4）：e0122397. DOI：10.1371/journal.pone.0122397.
[75]	CHEN M, TANG T C, WANG Y，et al. Randomised clinical trial：Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther，2018，48（2）：160-168. DOI：10.1111/apt.14817.
[76]	RAHIMI R, ABDOLLAHI M. Herbal medicines for the management of irritable bowel syndrome：a comprehensive review[J]. World J Gastroenterol，2012，18（7）：589-600. DOI：10.3748/wjg.v18.i7.589.
[77]	世界卫生组织推荐针灸治疗的43种病症[J]. 中医药临床杂志，2012，24（6）：519.
[78]	MANHEIMER E, CHENG K, WIELAND L S，et al. Acupuncture for treatment of irritable bowel syndrome[J]. Cochrane Database Syst Rev，2012，5（5）：CD005111. DOI：10.1002/14651858.CD005111.pub3.
[79]	ZHENG H, LI Y, ZHANG W，et al. Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea：a randomized controlled trial[J]. Medicine，2016，95（24）：e3884. DOI：10.1097/MD.0000000000003884.
[80]	PEI L X, GENG H, GUO J，et al. Effect of acupuncture in patients with irritable bowel syndrome：a randomized controlled trial[J]. Mayo Clin Proc，2020，95（8）：1671-1683. DOI：10.1016/j.mayocp.2020.01.042.
[81]	陈碧玮，陈少宗，方剑乔，等. 针灸治疗肠易激综合征的神经生物学机制研究进展及问题[J]. 针刺研究，2021，46（10）：885-892. DOI：10.13702/j.1000-0607.201262.
[82]	陈瑞琳，王洪，牛柯敏，等. 肠易激综合征中医外治法研究概况[J]. 北京中医药，2019，38（3）：296-299. DOI：10.16025/j.1674-1307.2019.03.030.
[83]	王雅琴，张瑞春. 中医推拿对治疗肠易激综合征的疗效[J]. 世界最新医学信息文摘，2018，18（61）：144，146. DOI：10.19613/j.cnki.1671-3141.2018.61.103.
[84]	BU F L, HAN M, LU C L，et al. A systematic review of Tuina for irritable bowel syndrome：recommendations for future trials[J]. Complement Ther Med，2020，52：102504. DOI：10.1016/j.ctim.2020.102504.
[85]	SPILLER R, AZIZ Q, CREED F，et al. Guidelines on the irritable bowel syndrome：mechanisms and practical management[J]. Gut，2007，56（12）：1770-1798. DOI：10.1136/gut.2007.119446.

Review of Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome

补充与替代疗法治疗肠易激综合征的研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 85

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	FENG Yuxi, WANG Jinjin, CAI Yi, ZHU Runzhi, ZHU Qin. Research Progress on Protein Lactylation in Kidney Diseases [J]. Chinese General Practice, 2026, 29(21): 3056-3063.
[2]	LI Wenping, CHEN Jianhua, XU Jiapei, JIN Xue, PAN Zihan, CHI Chunhua. A Scoping Review on the Empowerment of Community Elderly Health Services by Digital-Intelligent Health Management Platforms [J]. Chinese General Practice, 2026, 29(21): 2938-2949.
[3]	CHENG Yu, HAN Shiyao, SUN Ping, XIANG Juan, YANG Hui, LI Dongze, ZHENG Li, LIAO Xiaoyang. Analysis of Socioeconomic and Demographic Challenges in Chronic Disease Management [J]. Chinese General Practice, 2026, 29(20): 2800-2807.
[4]	CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592.
[5]	ZHANG Mingyue, HOU Yan. Research Progress of Exhaled Nitric Oxide and Alveolar Nitric Oxide in Interstitial Lung Diseases [J]. Chinese General Practice, 2026, 29(18): 2571-2576.
[6]	MA Xiaoyu, MA Xiaomei, WU Guozhi, ZHENG Ya, GUO Qinghong. Research Progress of Neutrophil Extracellular Traps in Gastric Cancer [J]. Chinese General Practice, 2026, 29(17): 2425-2432.
[7]	LI Jiawei, GE Aoqi, GAO Xinyi, LI Juanjuan, YUAN Beibei. The Concept, Connotation, and Pathways of the Integration of Medical Care and Preventive Services in China: a Systematic Review [J]. Chinese General Practice, 2026, 29(16): 2156-2166.
[8]	WANG Yang, JIN Hua, YANG Sen, YANG Hui, YU Dehua. Reconfiguring the Functional Features of Primary Care in a Non-gatekeeping Context: a 15-Year Mixed-methods Systematic Review from China [J]. Chinese General Practice, 2026, 29(16): 2140-2155.
[9]	ZOU Jian, LI Wanping, GE Handa, JIN Zhe, RUFEINA· Tuerxun, LI Juan, WEI Anhua, FENG Da. Study on Potentially Inappropriate Medication Use among the Community Elderly Patients in Hubei Province [J]. Chinese General Practice, 2026, 29(13): 1759-1765.
[10]	ZHANG Qiang, ZHAO Wenxia, WANG Ziyi, YAN Le, LIANG Haowei, WANG Jinfan, FANG Jinhua, LU Cuncun. Interpretation of the Reporting Guideline for Systematic Reviews of Outcome Measurement Instruments (PRISMA-COSMIN for OMIs 2024) [J]. Chinese General Practice, 2026, 29(13): 1766-1775.
[11]	YE Xinying, YIN Ankang, LIU Dingling, LYU Xiang, WANG Yi. The Development of General Practice Department in General Hospitals under the DIP Payment Model [J]. Chinese General Practice, 2026, 29(11): 1378-1384.
[12]	SHI Yufeng, LU Chenxia, LYU Anqi, LI Xiaodong. Research Progress on the Relationship between Veillonella and Liver Diseases Based on the Theory of Intestinal-hepatic Axis [J]. Chinese General Practice, 2026, 29(11): 1488-1496.
[13]	SUN Yuchen, SHI Yaxin, SHI Wei. Advancements in the Treatment of Endometrial Hypofunction Diseases Using Menstrual Blood-derived Endometrium Stem Cells Combined with Traditional Chinese Medicine for Tonifying Kidney and Activating Blood in Regenerative Medicine [J]. Chinese General Practice, 2026, 29(11): 1481-1487.
[14]	WANG Gaoming, WANG Minghang, YANG Jiang, MENG Yuanyuan, ZHAO Di, DONG Xiaosheng. Systematic Evaluation and Reflection on the Quality of Bronchial Asthma Guidelines in China [J]. Chinese General Practice, 2026, 29(10): 1239-1245.
[15]	WANG Yuqi, YE Ruixue, GAO Yan, XUE Kaiwen, ZHOU Jing, LI Dongxia, HAO Yingzi, LI Xiaoxuan, WANG Yulong. Rehabilitation Grading Diagnosis System of the Domestic and Foreign Development Present Situation and Application Requirements [J]. Chinese General Practice, 2026, 29(10): 1250-1255.